What are Bispecific Proteins ?

Bispecific proteins have two binding domains for binding two distinct targets. These proteins have versatile properties that make them advantageous for use as tools in biochemical techniques or as therapeutics. Our current research includes designing novel soluble reagents for improving in vitro techniques and to design and assess novel bispecific therapeutics with immunomodulatory properties. 

T-CEP (T-Cell Expansion Protein) constructs

T-CEP (T-Cell Expansion Protein) combines a single chain variable fragment (ScFV) against CD28 with a ScFV against CD3 in one small soluble protein to produce a highly potent small ex vivo T-cell activator and expander. This technology improves on currently available soluble method for T-cell expansion, and has potential for application in the field of adoptive cell therapy, where efficient expansion of effective T-cells is needed.


Figure 1. Side view of CD28-CD3 ScFV bispecific construct ribbon structure as predicted using Deepmind Alphafold 2.0 under a Google Colab iteration [CD28 ScFV, CD3 ScFV, scFv heavy and light chain, general linker, 6x His Tag]    (https://colab.research.google.com/github/sokrypton/ColabFold/blob/main/beta/AlphaFold2_advanced.ipynb#scrollTo=KAZj6CBZTkJM) 

Bispecific proteins for tissue-specific targeting and accumulation

The use of the bispecific protein format for tissue-specific accumulation of therapeutic cargo is also being explored. By selecting two appropriate domains, we are studying the effectiveness of delivering immunomodulatory proteins to a specific antigen as means of potentiating the therapeutic effect and reducing systemic side effects in the treatment of inflammatory diseases.

Selected publication from our group:

1. Matus EI, Sparkes A, Gariépy J (2020) A soluble activator that favors the ex vivo expansion of CD8+CD27+ T cells. JCI Insight. 5(22):e141293


Last updated on Nov-5-2021